<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="92677"><DrugName>ATYR-1940</DrugName><DrugNamesKey><Name id="43051365">Resolaris</Name></DrugNamesKey><DrugSynonyms><Name><Value>ATYR-1940</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Resolaris</Value><Types><Type>Trade Name</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1031876">aTyr Pharma Inc</CompanyOriginator><CompaniesSecondary><Company id="1031876">aTyr Pharma Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1031876" type="Company"><TargetEntity id="4297313459" type="organizationId">aTyr Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="2020" type="ciIndication"><TargetEntity id="10013801" type="MEDDRA"/><TargetEntity id="D020388" type="MeSH"/><TargetEntity id="98896" type="ORPHANET"/><TargetEntity id="-2123687174" type="omicsDisease"/><TargetEntity id="143" type="siCondition"/></SourceEntity><SourceEntity id="2466" type="ciIndication"><TargetEntity id="10022611" type="MEDDRA"/><TargetEntity id="D017563" type="MeSH"/><TargetEntity id="-792714508" type="omicsDisease"/><TargetEntity id="1231" type="siCondition"/></SourceEntity><SourceEntity id="3250" type="ciIndication"><TargetEntity id="D049288" type="MeSH"/><TargetEntity id="263" type="ORPHANET"/><TargetEntity id="-1070558393" type="omicsDisease"/><TargetEntity id="2684" type="siCondition"/></SourceEntity><SourceEntity id="3745" type="ciIndication"><TargetEntity id="10064087" type="MEDDRA"/><TargetEntity id="D020391" type="MeSH"/><TargetEntity id="269" type="ORPHANET"/><TargetEntity id="-1021872901" type="omicsDisease"/><TargetEntity id="2504" type="siCondition"/></SourceEntity><SourceEntity id="PTGT-14953" type="ciTarget"><TargetEntity id="173451443230353" type="siTarget">Histidine--tRNA ligase, cytoplasmic</TargetEntity><TargetEntity id="-622682708" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="2020">Duchenne dystrophy</Indication><Indication id="2466">Interstitial lung disease</Indication><Indication id="3250">Limb girdle muscular dystrophy</Indication><Indication id="3745">Facioscapulohumeral muscular dystrophy</Indication></IndicationsSecondary><ActionsPrimary><Action id="84453">Histidyl tRNA synthetase stimulator</Action></ActionsPrimary><Technologies><Technology id="901">Recombinant enzyme</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="648">Intravenous formulation</Technology></Technologies><LastModificationDate>2018-12-18T17:13:54.000Z</LastModificationDate><ChangeDateLast>2019-01-08T00:00:00.000Z</ChangeDateLast><AddedDate>2014-09-18T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1031876" linkType="Company"&gt;aTyr Pharma&lt;/ulink&gt; was developing ATYR-1940 (Resolaris), a recombinant Physiocrine-based human histidyl-tRNA synthetase, for the potential iv treatment of facioscapulohumeral muscular dystrophy (FMD; FSHD), early onset FSHD, limb-girdle muscular dystrophy (LGMD) 2B, and Duchenne muscular dystrophy (DMD) [&lt;ulink linkID="1594048" linkType="Reference"&gt;1594048&lt;/ulink&gt;], [&lt;ulink linkID="1626707" linkType="Reference"&gt;1626707&lt;/ulink&gt;], [&lt;ulink linkID="1629372" linkType="Reference"&gt;1629372&lt;/ulink&gt;], [&lt;ulink linkID="1654134" linkType="Reference"&gt;1654134&lt;/ulink&gt;], [&lt;ulink linkID="1702749" linkType="Reference"&gt;1702749&lt;/ulink&gt;], [&lt;ulink linkID="1711425" linkType="Reference"&gt;1711425&lt;/ulink&gt;], [&lt;ulink linkID="1673928" linkType="Reference"&gt;1673928&lt;/ulink&gt;], [&lt;ulink linkID="1909960" linkType="Reference"&gt;1909960&lt;/ulink&gt;]. In January 2017, the company was seeking to outlicense the program to a partner for development [&lt;ulink linkID="1892402" linkType="Reference"&gt;1892402&lt;/ulink&gt;], however in March 2018, aTyr stated that clinical development of the drug would not be continued without a strategic partnership [&lt;ulink linkID="2015832" linkType="Reference"&gt;2015832&lt;/ulink&gt;]; in November 2018, the company stated that it had not succeeded in establishling a strategic partnership or other collaborative arrangement for ATYR-1940 and development was presumed to  be discontinuedÂ [&lt;ulink linkID="2105159" linkType="Reference"&gt;2105159&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In August 2014, a phase Ib/II trial in FMD was initiated [&lt;ulink linkID="1594048" linkType="Reference"&gt;1594048&lt;/ulink&gt;], [&lt;ulink linkID="1646432" linkType="Reference"&gt;1646432&lt;/ulink&gt;]; in March 2016, data were reported [&lt;ulink linkID="1747466" linkType="Reference"&gt;1747466&lt;/ulink&gt;]. In November 2015, a phase Ib/II trial in early onset FSHD was initiated [&lt;ulink linkID="1711425" linkType="Reference"&gt;1711425&lt;/ulink&gt;]; in April 2017, data were reported [&lt;ulink linkID="1920876" linkType="Reference"&gt;1920876&lt;/ulink&gt;]. In October 2015, a phase Ib/II trial for LGMD2B was initiated [&lt;ulink linkID="1702749" linkType="Reference"&gt;1702749&lt;/ulink&gt;]; in December 2016, topline data were reported  [&lt;ulink linkID="1884662" linkType="Reference"&gt;1884662&lt;/ulink&gt;]; in January 2017, phase I/II trials in FSHD and LGMD were ongoing [&lt;ulink linkID="1892402" linkType="Reference"&gt;1892402&lt;/ulink&gt;].  In March 2017, the company listed the drug as being under evaluation for the treatment of DMD [&lt;ulink linkID="1909960" linkType="Reference"&gt;1909960&lt;/ulink&gt;]. In May 2017, the company was planning to initiate a randomized, placebo-controlled trial with Resolaris following the identification of a pharmacodynamic assay [&lt;ulink linkID="1926979" linkType="Reference"&gt;1926979&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The drug was previously in development for  interstitial lung disease (ILD). In January 2016, the  program was listed as being in phase I development  for ILD [&lt;ulink linkID="1738614" linkType="Reference"&gt;1738614&lt;/ulink&gt;], and aTyr was planning to initiate a clinical program in rare pulmonary diseases with an immune component (RPIC) in patients with ILD [&lt;ulink linkID="1726192" linkType="Reference"&gt;1726192&lt;/ulink&gt;]; however,   no development has  been reported since that time.  &lt;/para&gt;&lt;para&gt;aTyr Pharma is also investigating &lt;ulink linkID="99829" linkType="Drug"&gt;stalaris&lt;/ulink&gt; for the potential treatment of severe pulmonary diseases with an immune and fibrotic component [&lt;ulink linkID="1892402" linkType="Reference"&gt;1892402&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;ATYR-1940 is protected by a number of of patent families. The first patent family encompasses patents jointly owned by aTyr and its subsidiary &lt;ulink linkID="1056941" linkType="Company"&gt;Pangu Biopharma&lt;/ulink&gt; and includes &lt;ulink linkID="PA7619267" linkType="Patent"&gt;US-08835387&lt;/ulink&gt; and &lt;ulink linkID="PA8122963" linkType="Patent"&gt;US-09273302&lt;/ulink&gt; patents, both  expected to expire in 2033; by March 2018, granted patents  from this family had been issued in several jurisdictions, including  Australia, Europe,  Japan, New Zealand and South Africa; patent applications were pending in the US, Brazil, Canada, China, India, South Korea, Mexico, New Zealand and Russia. A second patent family wholly owned by aTyr and covering the drug and related proteins encompasses further issued patents and pending patent applications, including issued &lt;ulink linkID="PA7354442" linkType="Patent"&gt;US-09127268&lt;/ulink&gt;, &lt;ulink linkID="PA7136681" linkType="Patent"&gt;EP-2509625&lt;/ulink&gt;, &lt;ulink linkID="PA7345022" linkType="Patent"&gt;JP-5819314&lt;/ulink&gt;, Chinese Patent  ZL 201080061989.7, and Australian patent 2010327926, as well as two other issued US patents, set to expire in 2030 and 2031 and an issued patent in Hong Kong; as of March 2018, related applications were pending in the US, Australia, Canada, Europe, China, and Japan. Patents issuing from these applications, if any, are expected to expire in 2030 plus any patent term extension. Also in March 2018, patent applications to specific methods of use of the drug and related proteins, and disease polymorphisms of HARS were pending; by March 2017, these applications had been filed in the US and in some cases under the Patent Cooperation Treaty (PCT); if issued, these patents are anticipated to expire between 2033 and 2037 [&lt;ulink linkID="1909960" linkType="Reference"&gt;1909960&lt;/ulink&gt;],  [&lt;ulink linkID="2015832" linkType="Reference"&gt;2015832&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In January 2017, the FDA granted Fast Track designation  for LGMD2B [&lt;ulink linkID="1893358" linkType="Reference"&gt;1893358&lt;/ulink&gt;], [&lt;ulink linkID="1892402" linkType="Reference"&gt;1892402&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The company's IND was placed on full clinical hold in 2014 to address the issue of the comparability of the drug substance used in preclinical toxicology studies to that previously used with that proposed for use in the US clinical trial. aTyr submitted a response, and in January 2015, the FDA removed the IND from full clinical hold, allowing a phase Ib/II trial in the US. The IND was again placed on partial clinical hold, which prohibited the evaluation of ATYR-1940 at doses higher than 3.0 mg/kg; the FDA lifted the partial clinical hold in December 2016 [&lt;ulink linkID="1892402" linkType="Reference"&gt;1892402&lt;/ulink&gt;], [&lt;ulink linkID="2105159" linkType="Reference"&gt;2105159&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2016, the FDA granted Fast Track status for the treatment of FMD [&lt;ulink linkID="1865911" linkType="Reference"&gt;1865911&lt;/ulink&gt;]. In April 2015, the FDA granted Orphan Drug Designation for FMD [&lt;ulink linkID="1654134" linkType="Reference"&gt;1654134&lt;/ulink&gt;]. In February 2017, the FDA granted Orphan Drug Designation for LGMD [&lt;ulink linkID="1904118" linkType="Reference"&gt;1904118&lt;/ulink&gt;], [&lt;ulink linkID="1905283" linkType="Reference"&gt;1905283&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In January 2015,  the EMA's COMP adopted a positive opinion recommending ATYR-1940  for Orphan Drug designation for the treatment of FMD [&lt;ulink linkID="1626707" linkType="Reference"&gt;1626707&lt;/ulink&gt;]; in February 2015, the EC granted an Orphan drug designation for the drug for FMD [&lt;ulink linkID="1634683" linkType="Reference"&gt;1634683&lt;/ulink&gt;]. In January 2017, the COMP recommended the product  for Orphan status for treatment of LGMD [&lt;ulink linkID="1897364" linkType="Reference"&gt;1897364&lt;/ulink&gt;]; in February 2017, the EMA granted the product Orphan Drug designation for the treatment of LGMD [&lt;ulink linkID="1905525" linkType="Reference"&gt;1905525&lt;/ulink&gt;], [&lt;ulink linkID="1913059" linkType="Reference"&gt;1913059&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In May 2017, the company was planning to initiate a randomized, placebo-controlled trial with Resolaris following the identification of a pharmacodynamic assay [&lt;ulink linkID="1926979" linkType="Reference"&gt;1926979&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2017, the placebo-controlled, randomized, single-ascending dose, safety, phase I trial ATYR1940-C-001 (001 Study) had been conducted in healthy subjects (n = 32). Single doses of 0.1, 0.3, 1 and 3 mg/kg had been administered in 6 subjects of each of the four dose arms [&lt;ulink linkID="1909960" linkType="Reference"&gt;1909960&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2017, data were presented at the 35th Annual JP Morgan Healthcare Conference in San Francisco, CA, comparing the overall mean manual muscle test (MMT) change at week 14 across three trials (002, 003 and 004). Those patients administered placebo and low doses of ATYR-1940 (1.0 mg/kg in trial 004) showed a negative change from baseline following treatment, with those FSHD patients treated at 3.0 mg/kg in trial 002 showing a small positive effect. In comparison, in early onset FSDH (3.0 mg/kg trial 003) and LGMD patients (3.0 mg/kg biw trial 004), there was a significant improvement observed, with 50 to 78% of patients in the ATYR-1940 dose groups having increased scores [&lt;ulink linkID="1892402" linkType="Reference"&gt;1892402&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2016, a long-term extension, phase Ib/II study  (&lt;ulink linkID="265953" linkType="Protocol"&gt;NCT02836418&lt;/ulink&gt;; ATYR1940-C-006) in adult FSHD, early-onset FSHD, and LGMD2B patients from  the ongoing 003 and 004 trials was initiated [&lt;ulink linkID="1787198" linkType="Reference"&gt;1787198&lt;/ulink&gt;]. In November 2016, an update from the rollover patients was expected to be announced in first half of 2017 [&lt;ulink linkID="1873830" linkType="Reference"&gt;1873830&lt;/ulink&gt;]. By March 2017, the trial had closed enrollment with a total of eight patients recruited. At that time, the trial was expected to conclude by 1H17 as the company believed that primary endpoints had been met. An update on the trial was expected in mid-2017 [&lt;ulink linkID="1909960" linkType="Reference"&gt;1909960&lt;/ulink&gt;]. By August 2017, the trial had been completed with no significant adverse events being observed. The trial demonstrated that all patients remained Jo-1 antibody negative throughout  including two patients who showed transient Jo-1 antibody levels above the protocol-defined cut-off for continuation in the trial [&lt;ulink linkID="1953596" linkType="Reference"&gt;1953596&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2015, the first patient was dosed in a newly initiated international, multi-center, open label, long term-safety extension, phase I/II trial (&lt;ulink linkID="238631" linkType="Protocol"&gt;NCT02531217&lt;/ulink&gt;; ATYR1940-C-005Â  2015-001912-36) to  assess the safety, tolerability and biological activity of Resolaris in adult patients (expected n = 32) with  FSHD from the completed NCT02239224 trial [&lt;ulink linkID="1693701" linkType="Reference"&gt;1693701&lt;/ulink&gt;], [&lt;ulink linkID="1884662" linkType="Reference"&gt;1884662&lt;/ulink&gt;]. In August 2016, dosing was ongoing  [&lt;ulink linkID="1787198" linkType="Reference"&gt;1787198&lt;/ulink&gt;].  In December 2016, interim dataÂ from the trial were reported. Among the four patients who received weekly doses of 3.0 mg/kg of the drug for a period of 6 months, there were no significant trends in worsening or improvement in either MMT or INQoL scores and the drug was tolerated [&lt;ulink linkID="1884662" linkType="Reference"&gt;1884662&lt;/ulink&gt;]. By March 2017, the trial had closed enrollment with a total of 9 patients recruited. At that time, the trial was expected to conclude by 1H17 as the company believed that primary endpoints had been met  [&lt;ulink linkID="1909960" linkType="Reference"&gt;1909960&lt;/ulink&gt;]. By August 2017, the trial had been completed with no significant adverse events being observed. The trial demonstrated that all patients remained Jo-1 antibody negative throughout including three patients who showed transient Jo-1 antibody levels above the protocol-defined cut-off and other three patients showed transient, mild-to-moderate infusion related reactions and were discontinued per protocol  [&lt;ulink linkID="1953596" linkType="Reference"&gt;1953596&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2016, the  program was listed as being in phase II development  for ILD. At that time, a phase Ib/II trial   in ILD  was planned to be initiated by the end of 2016 [&lt;ulink linkID="1738614" linkType="Reference"&gt;1738614&lt;/ulink&gt;]. In July 2015, the company planned to initiate a phase Ib/II trial in ILD  in the first half of 2016 [&lt;ulink linkID="1678698" linkType="Reference"&gt;1678698&lt;/ulink&gt;]. In January 2016, the  program was listed as being in phase I development  for ILD. At that time, a phase Ib/II trial   in ILD  was planned to be initiated by the end of 2016 [&lt;ulink linkID="1738614" linkType="Reference"&gt;1738614&lt;/ulink&gt;]; no development has since been reported. &lt;/para&gt;&lt;para&gt;In July 2015, the company planned to initiate a phase Ib/II trial in   the fourth  quarter of 2015 [&lt;ulink linkID="1678698" linkType="Reference"&gt;1678698&lt;/ulink&gt;]. In October 2015, the open-label, intra-patient dose-escalation, international, phase Ib/II trial was initiated to evaluate the safety, efficacy, tolerability and immunogenicity of Resolaris in adult patients (expected n = 16) with LGMD2B that also includes up to eight patients with FSHD in the US and Europe [&lt;ulink linkID="1702749" linkType="Reference"&gt;1702749&lt;/ulink&gt;]. In January 2016, the first patient was dosed in the trial [&lt;ulink linkID="1726192" linkType="Reference"&gt;1726192&lt;/ulink&gt;].	In May 2016, enrollment was completed  [&lt;ulink linkID="1761207" linkType="Reference"&gt;1761207&lt;/ulink&gt;]. By August 2016, the trial (&lt;ulink linkID="243430" linkType="Protocol"&gt;NCT02579239&lt;/ulink&gt;; ATYR1940-C-004Â  2015-001910-88; 004) had completed enrollment with 18 patients [&lt;ulink linkID="1787198" linkType="Reference"&gt;1787198&lt;/ulink&gt;], [&lt;ulink linkID="1796967" linkType="Reference"&gt;1796967&lt;/ulink&gt;]. In December 2016, the trial was completed and top-line data were reported. The trial was conducted in 6 clinical sites for a period of 12 weeks and patients were assigned to two treatment groups; group A with 4 patients treated for FSHD received infusions of Resolaris with the highest dosing of up to 1.0 mg/ kg biweekly for a period of 4 week; group B with 10 patients treated for LGMD and 	4 patients with FSHD received infusions of Resolaris with the highest dosing up to 3.0 mg/ kg biweekly for a period of 4 week.Â The patients with LGMD2B, 10 patients had overall stable INQoL score. The patients with FSHD, had overall stable INQoL score and 5 of 8 patients showed a small decrease in disease burden over the length of the trial. The drug was tolerated  [&lt;ulink linkID="1884662" linkType="Reference"&gt;1884662&lt;/ulink&gt;]. In January 2017, clinical data were presented at the 35th Annual JP Morgan Healthcare Conference in San Francisco, CA. ATYR-1940 was administered at 3 mg/kg (biw) during week 14 in a MMT measuring the muscle function of the patients. Of the total number of patients, muscle function decreased slightly from baseline in two patients; however, in the other seven, a marked improvement from baseline was observed, with 21.3% being the highest [&lt;ulink linkID="1892402" linkType="Reference"&gt;1892402&lt;/ulink&gt;].  In April 2017, further results were presented at the 69th AAN Annual Meeting in Boston, MA. Baseline mean overall MMT score increased by 6.2% among seven out of nine patients with LGMD2B/Miyoshi myopathy-type dysferlinopathies. Although 11 out of 18 patients were positive for anti-ATYR-1940 antibodies, none of the patients had high titers that could trigger testing in a neutralizing antibody assay. All treated patients reported at least one treatment-emergent adverse event (AE), and all treatment-emergent AEs  were mild or moderate in severity [&lt;ulink linkID="1920127" linkType="Reference"&gt;1920127&lt;/ulink&gt;], [&lt;ulink linkID="1920875" linkType="Reference"&gt;1920875&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, the company was planning to conduct trials for additional indications, including early onset FSHD, LGMD2B  and ILD [&lt;ulink linkID="1673928" linkType="Reference"&gt;1673928&lt;/ulink&gt;]. In November 2015, an international multi-center, open-label, placebo run-in, intra-patient dose escalation trial (&lt;ulink linkID="245845" linkType="Protocol"&gt;NCT02603562&lt;/ulink&gt;; ATYR1940-C-003; 2014-003346-27) was initiated in patients (expected n = 16) with early onset FSHD to assess the safety, tolerability, immunogenicity, and biological activity of Resolaris inÂ the first stage of the trial. 	The second stage of enrollment was expected to enroll up to eight patients [&lt;ulink linkID="1711425" linkType="Reference"&gt;1711425&lt;/ulink&gt;], [&lt;ulink linkID="1884662" linkType="Reference"&gt;1884662&lt;/ulink&gt;]. In December 2016, interim dataÂ were reported from the exploratory assessments ofÂ clinical activity of Resolaris in patients with early onset of FSHD at weekly doses of 0.3, 1.0 and 3.0 mg/ kg for a total of 12 weeks. The INQoL scores were relatively stable with two patients having slight decrease in disease burden and one patient showed an increase. The drug was 	tolerated [&lt;ulink linkID="1884662" linkType="Reference"&gt;1884662&lt;/ulink&gt;]. By March 2017, enrollment of the trial had been closed with a total of 8 patients recruited. At that time, the trial was expected to complete by 1H17 [&lt;ulink linkID="1909960" linkType="Reference"&gt;1909960&lt;/ulink&gt;]. In April 2017, data were reported from eight patients, aged 16 to 20 years old. An increase from baseline in their Manual Muscle Test was observed in 63% of patients (5 of 8) and an improvement in their Individualized Neuromuscular Quality of Life score was obtained in 67% of patients (4 of 6) [&lt;ulink linkID="1920876" linkType="Reference"&gt;1920876&lt;/ulink&gt;]. Later that month, similar data were presented at the American Academy of Neurology (AAN), annual meeting in Boston, MA [&lt;ulink linkID="1953596" linkType="Reference"&gt;1953596&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2014, a double-blind, randomized, multiple-ascending dose, phase Ib/II trial (&lt;ulink linkID="210308" linkType="Protocol"&gt;NCT02239224&lt;/ulink&gt;; ATYR1940-C-002, 2014-001753-17) to evaluate the safety, tolerability, pharmacokinetics and biological activity of ATYR-1940 in patients (expected n = 44) with FMD was initiated in France and planned to be initiated in the Netherlands. At that time, the trial was expected to complete in December 2015 [&lt;ulink linkID="1594048" linkType="Reference"&gt;1594048&lt;/ulink&gt;]. By January 2015, the trial had been initiated in the Netherlands and Italy [&lt;ulink linkID="1594048" linkType="Reference"&gt;1594048&lt;/ulink&gt;], [&lt;ulink linkID="1646432" linkType="Reference"&gt;1646432&lt;/ulink&gt;]. In January 2015, dosing was initiated in the phase Ib/II study [&lt;ulink linkID="1629372" linkType="Reference"&gt;1629372&lt;/ulink&gt;], [&lt;ulink linkID="1634683" linkType="Reference"&gt;1634683&lt;/ulink&gt;]. In May 2015, the trial was also recruiting in the US  [&lt;ulink linkID="1594048" linkType="Reference"&gt;1594048&lt;/ulink&gt;]. In August 2015, initial results from the trial were expected in late 2015 or early 2016 [&lt;ulink linkID="1685901" linkType="Reference"&gt;1685901&lt;/ulink&gt;]. In September 2015, data were expected in the fourth quarter of 2015 or in the first quarter of 2016 [&lt;ulink linkID="1693701" linkType="Reference"&gt;1693701&lt;/ulink&gt;]. In January 2016,  patient dosingÂ  was completed  [&lt;ulink linkID="1726192" linkType="Reference"&gt;1726192&lt;/ulink&gt;]; later that month, dosing was completed in third cohort of the trial [&lt;ulink linkID="1738614" linkType="Reference"&gt;1738614&lt;/ulink&gt;]. In March 2016, results from the trial were reported. Data demonstrated that Resolaris showed overall individualized neuromuscular quality of life (INQoL) score of 2.77, -1.22 and -3.78 for 0.3, 1.0 and 3.0 mg/kg at 1-month compared to 4.12 for placebo, and -9.90 for 3.0 mg/kg at 3-months compared to 15.55 for placebo in the intent-to-treat population of 20 patients. Furthermore, the composite manual muscle testing score showed improvement of approximately 0.5% with Resolaris compared to 1% decline in the placebo. The drug was tolerated [&lt;ulink linkID="1747466" linkType="Reference"&gt;1747466&lt;/ulink&gt;]. In October 2016, data from the FSHD-002 trial were presented at the 21st International Annual Congress of the World Muscle Society in Granada,Â Spain. The pharmacokinetics were dose-proportional and  consistent throughout the study. A significant improvement in Individualized Neuromuscular Quality of Life Assessment questionnaire responses and Manual Muscle Testing  measures, was observed. Patients in cohort 3 showed better improvement compared to cohort 1 and 2 patients [&lt;ulink linkID="1804776" linkType="Reference"&gt;1804776&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2015, an initial clinical trial for ILD was planned [&lt;ulink linkID="1712267" linkType="Reference"&gt;1712267&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1031876">aTyr Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="3745">Facioscapulohumeral muscular dystrophy</Indication><StatusDate>2018-11-14T00:00:00.000Z</StatusDate><Source id="2105159" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031876">aTyr Pharma Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="3250">Limb girdle muscular dystrophy</Indication><StatusDate>2018-11-14T00:00:00.000Z</StatusDate><Source id="2105159" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031876">aTyr Pharma Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="3745">Facioscapulohumeral muscular dystrophy</Indication><StatusDate>2018-11-14T00:00:00.000Z</StatusDate><Source id="2105159" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031876">aTyr Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="3250">Limb girdle muscular dystrophy</Indication><StatusDate>2018-11-14T00:00:00.000Z</StatusDate><Source id="2105159" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031876">aTyr Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="2020">Duchenne dystrophy</Indication><StatusDate>2018-11-14T00:00:00.000Z</StatusDate><Source id="2105159" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031876">aTyr Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2466">Interstitial lung disease</Indication><StatusDate>2017-07-14T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1031876">aTyr Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3745">Facioscapulohumeral muscular dystrophy</Indication><StatusDate>2015-04-22T00:00:00.000Z</StatusDate><Source id="1654134" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031876">aTyr Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3250">Limb girdle muscular dystrophy</Indication><StatusDate>2015-06-29T00:00:00.000Z</StatusDate><Source id="1673928" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031876">aTyr Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2466">Interstitial lung disease</Indication><StatusDate>2015-06-29T00:00:00.000Z</StatusDate><Source id="1673928" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031876">aTyr Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2020">Duchenne dystrophy</Indication><StatusDate>2017-03-16T00:00:00.000Z</StatusDate><Source id="1909960" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031876">aTyr Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3250">Limb girdle muscular dystrophy</Indication><StatusDate>2015-10-13T00:00:00.000Z</StatusDate><Source id="1702749" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031876">aTyr Pharma Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3250">Limb girdle muscular dystrophy</Indication><StatusDate>2015-10-13T00:00:00.000Z</StatusDate><Source id="1702749" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031876">aTyr Pharma Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3745">Facioscapulohumeral muscular dystrophy</Indication><StatusDate>2014-08-31T00:00:00.000Z</StatusDate><Source id="1594048" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031876">aTyr Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3745">Facioscapulohumeral muscular dystrophy</Indication><StatusDate>2015-05-21T00:00:00.000Z</StatusDate><Source id="1594048" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031876">aTyr Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2466">Interstitial lung disease</Indication><StatusDate>2016-01-14T00:00:00.000Z</StatusDate><Source id="1738614" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031876">aTyr Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="2020">Duchenne dystrophy</Indication><StatusDate>2018-03-20T00:00:00.000Z</StatusDate><Source id="2015832" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031876">aTyr Pharma Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="3745">Facioscapulohumeral muscular dystrophy</Indication><StatusDate>2018-03-20T00:00:00.000Z</StatusDate><Source id="2015832" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031876">aTyr Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="3745">Facioscapulohumeral muscular dystrophy</Indication><StatusDate>2018-03-20T00:00:00.000Z</StatusDate><Source id="2015832" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031876">aTyr Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="3250">Limb girdle muscular dystrophy</Indication><StatusDate>2018-03-20T00:00:00.000Z</StatusDate><Source id="2015832" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031876">aTyr Pharma Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="3250">Limb girdle muscular dystrophy</Indication><StatusDate>2018-03-20T00:00:00.000Z</StatusDate><Source id="2015832" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="1031876">aTyr Pharma Inc</OwnerCompany><Country id="US">US</Country><Indication id="3250">Limb girdle muscular dystrophy</Indication><AwardedIndication>Treatment of limb-girdle muscular dystrophy (LGMD) 2B</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-01-18T00:00:00.000Z</MileStoneDate><Source id="1893358" type="PR"/></Row><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="1031876">aTyr Pharma Inc</OwnerCompany><Country id="US">US</Country><Indication id="3745">Facioscapulohumeral muscular dystrophy</Indication><AwardedIndication>Treatment of facioscapulohumeral muscular dystrophy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2016-10-24T00:00:00.000Z</MileStoneDate><Source id="1865911" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1031876">aTyr Pharma Inc</OwnerCompany><Country id="US">US</Country><Indication id="3250">Limb girdle muscular dystrophy</Indication><AwardedIndication>Treatment of limb girdle muscular dystrophy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-02-28T00:00:00.000Z</MileStoneDate><Source id="1904118" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1031876">aTyr Pharma Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3250">Limb girdle muscular dystrophy</Indication><AwardedIndication>Treatment of limb-girdle muscular dystrophy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-02-27T00:00:00.000Z</MileStoneDate><Source id="1913059" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1031876">aTyr Pharma Inc</OwnerCompany><Country id="US">US</Country><Indication id="3250">Limb girdle muscular dystrophy</Indication><AwardedIndication>Treatment of patients with limb girdle muscular dystrophy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-02-23T00:00:00.000Z</MileStoneDate><Source id="1904118" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1031876">aTyr Pharma Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3250">Limb girdle muscular dystrophy</Indication><AwardedIndication>Treatment of limb-girdle muscular dystrophy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2017-01-19T00:00:00.000Z</MileStoneDate><Source id="1897364" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1031876">aTyr Pharma Inc</OwnerCompany><Country id="US">US</Country><Indication id="3745">Facioscapulohumeral muscular dystrophy</Indication><AwardedIndication>Treatment of facioscapulohumeral muscular dystrophy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2015-04-22T00:00:00.000Z</MileStoneDate><Source id="1654134" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1031876">aTyr Pharma Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3745">Facioscapulohumeral muscular dystrophy</Indication><AwardedIndication>Treatment of facioscapulohumeral muscular dystrophy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2015-02-12T00:00:00.000Z</MileStoneDate><Source id="1634683" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1031876">aTyr Pharma Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3745">Facioscapulohumeral muscular dystrophy</Indication><AwardedIndication>Treatment of facioscapulohumeral muscular dystrophy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2015-01-09T00:00:00.000Z</MileStoneDate><Source id="1626707" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-14953"><Name>Histidyl tRNA synthetase</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>2 references added [&lt;ulink url="utility.reference?i_reference_id=2094383" linkType="reference" linkID="2094383"&gt;2094383&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2105159" linkType="reference" linkID="2105159"&gt;2105159&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="2579949" number="WO-2013123432" title="Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="aTyr Pharma Inc" id="1031876"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>